Pulmonology Perspectives on Biomarker Testing in NSCLC: Multidisciplinary Management in an Era of Rapid Change

• Review the sentinel placement of the pulmonologist in the management of NSCLC, including their principal role in diagnostics, disease staging, and molecular testing.
• Evaluate clinical and patient-value driven factors that may help inform nodule evaluation and diagnostic strategies for pulmonologists, thus ensuring “the right tissue in the right amount from the right place for the right patient.”
• Demonstrate knowledge of guideline recommendations and practical considerations for the use of EBUS-TBNA techniques by pulmonologists, emphasizing the fundamentals of safely and effectively obtaining adequate tissue for diagnosis and molecular characterization.
• Describe the evolving role of targeted therapy and immunotherapy in NSCLC and analyze currently FDA-approved therapeutics across the NSCLC disease continuum, highlighting the role of molecular testing for guiding treatment and individualizing patient care.
• Explore the established utility of next-generation sequencing (NGS) and discuss the potential for emerging “next-generation” biomarkers in the NSCLC management paradigm.
• Apply patient-centric, evidence-supported collaborative care strategies to real-world, case-based scenarios in order to elucidate the pivotal role of the pulmonologist on the multidisciplinary team across the NSCLC continuum of care.

Supported through an independent educational grant from AstraZeneca.

It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.

CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Planner:
Kevin Ma, MD–has no relevant financial relationships to disclose in relation to the content of this activity.

Faculty:
Jill Feldman, MA–has disclosed that she is an advisor or consultant to Blueprint Medicine, Daiichi-Sankyo, EQRx, and Janssen. She also receives other financial or material support from AstraZeneca, Blueprint Medicine, and Takeda.
Hiren Mehta, MD–has no relevant financial relationships to disclose in relation to the content of this activity.
Raymond U. Osarogiagbon, MD–has disclosed that he is an advisor or consultant to AstraZeneca and Genentech. He also owns stock or is a shareholder in Eil Lilly, Gilead Sciences, and Pfizer.
Lynette M. Sholl, MD–has disclosed that she receives grants from Bristol Myers Squibb and Genentech. She is also an advisor or consultant to AstraZeneca, Eli Lilly, Genentech, and GV20 Therapeutics.
Gerard A. Silvestri, MD, MS–has disclosed that he receives research support from Amgen, Auris, Biodesix, Delfi, Exact Sciences, NCI, Nucleix, Olympus, PCORI, and SEER Inc. He is an advisor or consultant for Biodesix and Olympus.

Peer Reviewer:
Adam Fox, MD–has disclosed that he receives an Internal NIH grant: K12-CA157688, research support from the American Cancer Society and Olympus and is on the speakers bureau for the Association of Community Cancer Centers. He also owns self managed stock/shareholder of Merck.

CEC Staff:
Bryan C. Taylor, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Jessica Hall–has no relevant financial relationships to disclose in relation to the content of this activity.

Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.